Welcome to the Northern Ireland Cancer Network

Key hospital contacts

Belfast Health and Social Care Trust
All Royal Hospitals: (028) 9024 0503
Belfast City Hospital: (028) 9032 9241

Northern Health and Social Care Trust
Telephone: (028) 9442 4000

South Eastern Health and Social Care Trust
Ulster Hospital: (028) 9048 4511

Southern Health and Social Care Trust
Telephone: (028) 3833 4444

Western Health and Social Care Trust
Telephone: (028) 7134 5171

The Northern Ireland Cancer Network is a partnership of HSCNI organisations, academic, charity, cancer specialists and service users working in collaboration to deliver safe and effective care, improve cancer clinical outcomes and enhance patients and carers experience and quality of life.

Who are we & what do we do?

The Northern Ireland Cancer Network was formed in 2004 as Northern Ireland’s first Regional Clinical Network and links together the organisations that provide care for people with cancer across the 5 Health & Social care trusts in Northern Ireland.  The Network is part of the Health and Social Care Board. 

We do not actively deliver patient care, but work closely with service users, health professionals and managers to improve cancer services and to implement national and local NHS strategies. 

We:

  • support our members in the delivery of services that are evidence based
  • ensure equity of access and uniform quality of services for the population of Northern Ireland, and
  • work across organisational boundaries following the patient pathway.

Read more about NICaN

Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic bone metastases. However, responses to these therapies are typically brief, and the mechanism underlying androgen-independent progression is not clear. Here, we established what we believe to be the first human androgen receptor–negative prostate cancer xenografts whose cells induced an osteoblastic reaction in bone and in the subcutis of immunodeficient mice.

 

Click here to read the JCI research in full 

Pages